Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study

BackgroundThis analysis assessed baseline predictors of remission in patients with non-radiographic axial spondyloarthritis (nr-axSpA) who received open-label adalimumab therapy.MethodsABILITY-3 enrolled 673 adult patients with nr-axSpA who had objective evidence of inflammation by MRI or elevated h...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatic & musculoskeletal diseases open 2019-06, Vol.5 (1), p.e000917-e000917
Main Authors: Sieper, Joachim, Landewé, Robert, Magrey, Marina, Anderson, Jaclyn K, Zhong, Sheng, Wang, Xin, Lertratanakul, Apinya
Format: Article
Language:English
Subjects:
Adalimumab - pharmacology
Adalimumab - therapeutic use
Adult
Age
Anti-inflammatory agents
anti-TNF
Antigens
Antirheumatic Agents - pharmacology
Antirheumatic Agents - therapeutic use
Arthritis
Back pain
Consortia
disease activity
DMARD (biological)
Female
Humans
Immunotherapy
Inflammation
Information sharing
Leukocytes
Magnetic Resonance Imaging
Male
Middle Aged
Monoclonal antibodies
Odds Ratio
Patient assessment
Prognosis
Proteins
Remission (Medicine)
Remission Induction
Spondylarthritis - diagnosis
Spondylarthritis - drug therapy
Spondylarthritis - etiology
Spondylarthritis - metabolism
Spondyloarthritis
Systematic review
TNF inhibitors
Treatment Outcome
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundThis analysis assessed baseline predictors of remission in patients with non-radiographic axial spondyloarthritis (nr-axSpA) who received open-label adalimumab therapy.MethodsABILITY-3 enrolled 673 adult patients with nr-axSpA who had objective evidence of inflammation by MRI or elevated high-sensitivity C reactive protein at screening, active disease and an inadequate response to two or more non-steroidal anti-inflammatory drugs. Patients received adalimumab 40 mg every other week during a 28-week open-label lead-in period. Clinical remission was defined as Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS ID; score
ISSN:2056-5933
2056-5933
DOI:10.1136/rmdopen-2019-000917